Posted: Fri Apr 09, 2010 8:07 am Post subject: Development of Flu Vaccines Based on EB66 (Duck Cells)
From a press release about Glaxo and VIVALIS collaborating to develop new influenza vaccines based on VIVALIS' innovative EB66(R) cell line technology.
The EB66(R) cells replicate a wide range of human and animal viruses and are currently used or being evaluated for the production of viral vaccines.
The EB66(R) stem cell line technology derived from duck embryonic stem cells and are easily genetically engineered to efficiently express recombinant proteins of interest ( > 1 g/l). Monoclonal antibodies produced in EB66(R) cells have human-like glycosylation profile, with the remarkable additional feature of having reduced fucose content. This latter characteristic provides a better cytotoxic activity to antibodies, particularly useful in the treatment of cancer cells. _________________ https://twitter.com/mixin1771
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum